TÜBİTAK-ARDEB 1001 Project of Assoc. Prof. Dr. Amaç Fatih TUYUN
The project entitled “Synthesis of Targeted EGFR Inhibitors in NSCLC Treatment, Investigation of Mechanism of Their Anticancer Effects and Studies of Structural Dynamics” was deemed worthy of support within the framework of the TÜBİTAK-ARDEB 1001-Scientific and Technological Research Projects Support Program.
In the project which will be led by Koç University faculty member Assoc. Prof. Dr. Halil İbrahim ÇİFTÇİ, Assist. Prof. Dr. Hasan DEMİRCİ will participate in as an advisor, Assoc. Prof. Dr. Amaç Fatih TUYUN and Assoc. Prof. Dr. Belgin SEVER will participate in as a researcher. The project will progress with the contribution of different research groups from three different universities (Koç University, Anadolu University, and Istanbul University). In the project, it is aimed to prevent the development of resistance and the incidence of side effects, which are the biggest problems in NSCLC treatment, by identifying potential new anticancer compounds with mechanistic effects against NSCLC. In addition, it is aimed to optimize these new active molecules as a result of the dynamic structures that the target protein will form with the inhibitors.
The total budget of the project, which is targeted to be completed in 36 months, is approximately 720,000 TL and one (1) doctoral student will be supported as a scholarship.